ARS Pharmaceuticals, Inc. financial data

Symbol
SPRY on Nasdaq
Industry
Pharmaceutical Preparations
Location
11682 El Camino Real, Suite 120, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Silverback Therapeutics, Inc. (to 11/8/2022)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.01K % +5.34%
Debt-to-equity 3.39 % -13.7%
Return On Equity -22.6 % +6.7%
Return On Assets -21.8 % +6.19%
Operating Margin -2.36K % +99%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.2M shares +1.24%
Common Stock, Shares, Outstanding 97.1M shares +1.41%
Entity Public Float 382M USD +271%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 97M shares +1.52%
Weighted Average Number of Shares Outstanding, Diluted 97M shares +1.52%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.57M USD +8460%
Research and Development Expense 20M USD -7.49%
General and Administrative Expense 38.7M USD -1.14%
Operating Income (Loss) -60.5M USD +16.8%
Net Income (Loss) Attributable to Parent -49.1M USD +20.3%
Earnings Per Share, Basic -0.51 USD/shares +28.2%
Earnings Per Share, Diluted -0.51 USD/shares +28.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.7M USD -34.5%
Accounts Receivable, after Allowance for Credit Loss, Current 773K USD
Inventory, Net 715K USD
Assets, Current 209M USD -14.6%
Property, Plant and Equipment, Net 843K USD +36.6%
Operating Lease, Right-of-Use Asset 92K USD -69.3%
Intangible Assets, Net (Excluding Goodwill) 7.5M USD
Other Assets, Noncurrent 690K USD
Assets 218M USD -12.5%
Accounts Payable, Current 8.28M USD +179%
Employee-related Liabilities, Current 2.33M USD -28.9%
Accrued Liabilities, Current 3.65M USD -70.9%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 16.6M USD +48.7%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 16.6M USD +47.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 339K USD
Retained Earnings (Accumulated Deficit) -173M USD -39.6%
Stockholders' Equity Attributable to Parent 201M USD -15.3%
Liabilities and Equity 218M USD -12.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.71M USD +46%
Net Cash Provided by (Used in) Financing Activities 258K USD -80.4%
Net Cash Provided by (Used in) Investing Activities -8.51M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 97.1M shares +1.41%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15M USD +87.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.7M USD -34.5%
Deferred Tax Assets, Valuation Allowance 29M USD +63.6%
Deferred Tax Assets, Gross 29M USD +63.6%
Operating Lease, Liability 102K USD -68.8%
Depreciation 11K USD -45%
Payments to Acquire Property, Plant, and Equipment 83K USD -57%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48.6M USD +21.3%
Lessee, Operating Lease, Liability, to be Paid 104K USD -70%
Property, Plant and Equipment, Gross 748K USD +14.7%
Operating Lease, Liability, Current 102K USD -56.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 42K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 62K USD +3.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -90%
Lessee, Operating Lease, Liability, to be Paid, Year Three 42K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.1M USD +95.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.95M USD +93.8%
Operating Lease, Payments 1.99M USD +14.1%
Additional Paid in Capital 374M USD +3.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 29.2M USD +61.9%
Share-based Payment Arrangement, Expense 12.5M USD +7.07%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%